Table 1.
Clinical characteristics of PMA subjects in the training and test sets.
| Training set (n = 116) | Test set (n = 52) | Whole set (n = 168) | p | |
|---|---|---|---|---|
| Age, mean (SD), y | 45.59 (12.38) | 44.96 (11.63) | 45.39 (12.12) | 0.758† |
| Sex, No. (%) | 0.899§ | |||
| Male | 57 (49.14) | 25 (48.08) | 82 (48.81) | |
| Female | 59 (50.86) | 27 (51.92) | 86 (51.19) | |
| Endocrine level, No. (%) | 0.214§ | |||
| Non-functioning | 71 (61.21) | 37 (71.15) | 108 (64.29) | |
| Functioning | 45 (38.79) | 15 (28.85) | 60 (35.71) | |
| Height, median (IQR), mm | 30.73 (20.42-41.04) | 31.82 (19.21-44.43) | 30.96 (25.81-36.93) | 0.284‡ |
| Residual tumor, No. (%) | 0.584§ | |||
| Without | 43 (37.07) | 17 (32.69) | 60 (35.71) | |
| With | 73 (62.93) | 35 (67.31) | 108 (64.29) | |
| Invasion, No. (%) | 0.578§ | |||
| No | 33 (28.45) | 17 (32.69) | 50 (29.76) | |
| Yes | 83 (71.55) | 35 (67.31) | 118 (70.24) | |
| Surgical methods, No. (%) | 0.686§ | |||
| Craniotomy | 29 (25.00) | 12 (23.08) | 41 (24.40) | |
| Trans-sphenoidal | 59 (50.86) | 30 (57.69) | 89 (52.98) | |
| Endoscopic | 28 (24.14) | 10 (19.23) | 38 (22.62) | |
| The IHC subtypes, No. (%) | 0.906& | |||
| Immunonegative | 48 (41.38) | 25 (48.08) | 73 (43.45) | |
| GH-positive | 6 (5.17) | 1 (1.92) | 7 (4.17) | |
| PRL-positive | 5 (4.31) | 3 (5.77) | 8 (4.76) | |
| ACTH-positive | 11 (9.48) | 3 (5.77) | 14 (8.33) | |
| FSH-LH-positive | 22 (18.97) | 8 (15.38) | 30 (17.86) | |
| TSH-positive | 2 (1.72) | 1 (1.92) | 3 (1.79) | |
| Plurihormonal | 22 (18.97) | 11 (21.15) | 33 (19.64) |
ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; GH, growth hormone; IHC, immunohistochemistry; IQR, interquartile range; LH, luteinizing hormone; No, number; PRL, prolactin; SD, standard deviation; TSH, thyroid-stimulating hormone.
†
Two-sided independent sample t-test.
‡
Mann—Whitney U-test.
§
Pearson's χ2 test.
&
Fisher's precision probability test.